Correspondence 0001493152-22-034563 from Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc.
Date: Dec. 6, 2022 · CIK: 0001716947 · Accession: 0001493152-22-034563
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268038
Letter
Ensysce Biosciences, Inc.
Ivanhoe Avenue, Suite 201
La Jolla, California 92037
December 6, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, NE
Washington, D.C. 20549
Attention: Alan Campbell, Esq.
Re: Ensysce Biosciences, Inc.
Registration Statement on Form S-1, as amended
SEC File No. 333-268038
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-268038) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 5:00 PM, Eastern Time, on December 6, 2022, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Gregory Rubis at (609) 951-4105.
Please direct any questions or comments concerning this request to Mr. Rubis of Troutman Pepper Hamilton Sanders LLP.
ENSYSCE BIOSCIENCES, INC.
By: /s/ Lynn Kirkpatrick
Name: Lynn Kirkpatrick
Title:
CEO
Cc: Eric D. Kline, Troutman Pepper Hamilton Sanders LLP
Gregory Rubis, Troutman Pepper Hamilton Sanders LLP
Show Raw Text
CORRESP
1
filename1.htm
Ensysce
Biosciences, Inc.
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California 92037
December 6, 2022
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Attention:
Alan Campbell, Esq.
Re:
Ensysce
Biosciences, Inc.
Registration
Statement on Form S-1, as amended
SEC File No. 333-268038
Ladies
and Gentlemen:
Pursuant
to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc.
(the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1
(File No. 333-268038) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement
will become effective at 5:00 PM, Eastern Time, on December 6, 2022, or as soon thereafter as is practicable, or at such
other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement
has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Gregory
Rubis at (609) 951-4105.
Please
direct any questions or comments concerning this request to Mr. Rubis of Troutman Pepper Hamilton Sanders LLP.
ENSYSCE
BIOSCIENCES, INC.
By:
/s/
Lynn Kirkpatrick
Name:
Lynn
Kirkpatrick
Title:
CEO
Cc:
Eric
D. Kline, Troutman Pepper Hamilton Sanders LLP
Gregory
Rubis, Troutman Pepper Hamilton Sanders LLP